WO2000057187A3 - Diagnosis and treatment of multiple sclerosis - Google Patents

Diagnosis and treatment of multiple sclerosis Download PDF

Info

Publication number
WO2000057187A3
WO2000057187A3 PCT/US2000/007226 US0007226W WO0057187A3 WO 2000057187 A3 WO2000057187 A3 WO 2000057187A3 US 0007226 W US0007226 W US 0007226W WO 0057187 A3 WO0057187 A3 WO 0057187A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
diagnosis
treatment
patients
chlamydia
Prior art date
Application number
PCT/US2000/007226
Other languages
French (fr)
Other versions
WO2000057187A2 (en
WO2000057187A9 (en
Inventor
Charles W Stratton
William M Mitchell
Song-Yi Yao
Jason D Bannan
Asa Ljunggren-Rose
Subramaniam Sriram
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Priority to EP00916513A priority Critical patent/EP1166117A2/en
Priority to AU37604/00A priority patent/AU3760400A/en
Publication of WO2000057187A2 publication Critical patent/WO2000057187A2/en
Publication of WO2000057187A3 publication Critical patent/WO2000057187A3/en
Publication of WO2000057187A9 publication Critical patent/WO2000057187A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.
PCT/US2000/007226 1999-03-19 2000-03-17 Diagnosis and treatment of multiple sclerosis WO2000057187A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00916513A EP1166117A2 (en) 1999-03-19 2000-03-17 Diagnosis and treatment of multiple sclerosis
AU37604/00A AU3760400A (en) 1999-03-19 2000-03-17 Methods and reagents for the diagnosis and treatment of multiple sclerosis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12559899P 1999-03-19 1999-03-19
US60/125,598 1999-03-19
US17694000P 2000-01-18 2000-01-18
US17678400P 2000-01-18 2000-01-18
US17666200P 2000-01-18 2000-01-18
US60/176,662 2000-01-18
US60/176,784 2000-01-18
US60/176,940 2000-01-18

Publications (3)

Publication Number Publication Date
WO2000057187A2 WO2000057187A2 (en) 2000-09-28
WO2000057187A3 true WO2000057187A3 (en) 2001-04-19
WO2000057187A9 WO2000057187A9 (en) 2001-10-25

Family

ID=27494587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007226 WO2000057187A2 (en) 1999-03-19 2000-03-17 Diagnosis and treatment of multiple sclerosis

Country Status (3)

Country Link
EP (1) EP1166117A2 (en)
AU (1) AU3760400A (en)
WO (1) WO2000057187A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP2332549A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine
DK1571970T3 (en) * 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnosis and monitoring of diseases
PT2537524T (en) 2003-05-15 2016-09-05 Ampio Pharmaceuticals Inc Treatment of t-cell mediated diseases
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp Treatment of diseases
EP2765968A4 (en) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
MY167804A (en) 2011-10-10 2018-09-26 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
JP6231484B2 (en) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド Rhinitis treatment
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6723222B2 (en) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド Treatment of joint pathology
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN109453165B (en) * 2018-10-16 2021-02-05 丹诺医药(苏州）有限公司 Solid dispersion of rifamycin-nitroimidazole coupled molecule and application thereof
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
EP0439330A2 (en) * 1990-01-25 1991-07-31 Zeneca Limited Amplification methods
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5650405A (en) * 1993-05-05 1997-07-22 Palo Alto Medical Foundation Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S.
CN1156589A (en) * 1996-02-09 1997-08-13 王成武 Application of rifampicin in Linxiao'an medicine for treating gonorrhea
WO1998006435A2 (en) * 1996-08-14 1998-02-19 Vanderbilt University COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA)
WO1998010789A1 (en) * 1996-09-12 1998-03-19 Connaught Laboratories Limited Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
CN1190581A (en) * 1998-02-25 1998-08-19 高绪侠 Complex rifampin injection
WO1998050074A2 (en) * 1997-05-06 1998-11-12 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by chlamydia
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
EP0439330A2 (en) * 1990-01-25 1991-07-31 Zeneca Limited Amplification methods
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5650405A (en) * 1993-05-05 1997-07-22 Palo Alto Medical Foundation Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S.
CN1156589A (en) * 1996-02-09 1997-08-13 王成武 Application of rifampicin in Linxiao'an medicine for treating gonorrhea
WO1998006435A2 (en) * 1996-08-14 1998-02-19 Vanderbilt University COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA)
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
WO1998010789A1 (en) * 1996-09-12 1998-03-19 Connaught Laboratories Limited Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
WO1998050074A2 (en) * 1997-05-06 1998-11-12 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by chlamydia
CN1190581A (en) * 1998-02-25 1998-08-19 高绪侠 Complex rifampin injection
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BERTRAND A ET AL: "[ Ofloxacin (RU 43280). Clinical study]. L'ofloxacine (RU 43280). Etude clinique.", PATHOLOGIE BIOLOGIE, (1987 MAY) 35 (5) 629-33., XP000949930 *
DRANCOURT, MICHEL ET AL: "Oral rifampin plus ofloxacin for treatment of Staphylococcus infected orthopedic implants.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1993) VOL. 37, NO. 6, PP. 1214-1218., XP000949491 *
FREIDANK, HEIKE M. ET AL: "In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations", ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1808-1810, XP000949492 *
LAYH-SCHMITT GERLINDE; BENDL CLAUDIA; HILDT ULRIKE; DONG-SI TUAN ET AL.: "Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis", ANNALS OF NEUROLOGY, vol. 47, May 2000 (2000-05-01), pages 652 - 655, XP000949277 *
SRIRAM S; MITCHELL W; STRATTON C: "Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS", NEUROLOGY, vol. 50, February 1998 (1998-02-01), pages 571 - 572, XP000949278 *
SRIRAM SUBRAMANIAM; STRATTON CHARLES W; YAO SONG-YI; THARP ANTHONY; DING LINGMEI; BANNAN JASON D; MITCHELL WILLIAM M: "Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis", ANNALS OF NEUROLOGY, vol. 46, July 1999 (1999-07-01), pages 6 - 14, XP000949276 *
SRIRAM SUBRAMANIAM; YAO SONG-YI; STRATTON CHARLES; MITCHELL WILLIAM: "C. pneumoniae infection of the CNS in patients with relapsing remitting MS", NEUROLOGY (51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; TORONTO, ONTARIO, CANADA; APRIL 17-24, 1999), vol. 52, 12 April 1998 (1998-04-12), pages A558 - A559, XP000949282 *
YAO S -Y; SRIRAM S; STRATTON C; MITCHELL W: "Association between C. pneumoniae and MS", JOURNAL OF NEUROIMMUNOLOGY (FIFTH INTERNATIONAL CONGRESS OF THE INTERNATIONAL SOCIETY OF NEUROIMMUNOLOGY; MONTREAL, CANADA; AUGUST 23-27, 1998), vol. 90, 1 September 1998 (1998-09-01), pages 70, XP000949273 *
YAO SONGYI; SRIRAM S; MITCHELL W; STRATTON C; THARP A: "CNS infection with C. pneumoniae in MS", NEUROLOGY (50TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; MINNEAPOLIS, MINNESOTA, USA; APRIL 25-MAY 2, 1998), vol. 50, April 1998 (1998-04-01), pages A423 - A424, XP000949281 *
YAO SONG-YI; SRIRAM SUBRAMANIAM: "Reactivity of oligoclonal bands seen in CSF to C. pneumoniae antigens in patients with multiple sclerosis", NEUROLOGY (51ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY; TORONTO, ONTARIO, CANADA; APRIL 17-24, 1999), vol. 52, 12 April 1999 (1999-04-12), pages A559, XP000949279 *

Also Published As

Publication number Publication date
WO2000057187A2 (en) 2000-09-28
AU3760400A (en) 2000-10-09
WO2000057187A9 (en) 2001-10-25
EP1166117A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2000057187A3 (en) Diagnosis and treatment of multiple sclerosis
MXPA01008882A (en) Method and system for the discovery of cookies and other client information.
AU2001268331A1 (en) Methods for diagnosing and treating thalamocortical dysrhythmia
MXPA01007973A (en) Monitored vehicle tire and monitor retainer assembly.
AU2002243370A1 (en) Body supported activity and condition monitor
CA2429020A1 (en) Use of cci-779 as an antineoplastic agent
AU2001262943A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP2329829A3 (en) Use of uridine in combination with choline for the treatment of memory disorders
WO1995024650A3 (en) Methods of diagnosing and treating preeclampsia
EP1144639A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2003084384A3 (en) Diagnosis of flavivirus infection
EP0681787A3 (en) Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis.
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
HK1042523A1 (en) Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
ZA992192B (en) Humectant and lubricant solution for ophthalmic use.
CA2381354A1 (en) Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines
HK1039131A1 (en) Derivatives of octahydro-6,10-dioxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, the prepa ration process and the use thereof.
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
AU2002365941A1 (en) Methods of diagnosis, monitoring and treatment of fertility
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
CA2402668A1 (en) Use of cdp-choline for the prophylactic treatment of cerebral ischemia
WO2002072883A3 (en) Nucleotide carrier for diagnosing and treating oral diseases
AU6107999A (en) 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000916513

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000916513

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916513

Country of ref document: EP